Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic;
Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic.
Anticancer Res. 2021 Apr;41(4):2053-2058. doi: 10.21873/anticanres.14974.
To investigate potential associations between selected oncomarkers [carcinoembryonic antigen (CEA), C-terminus of cytokeratin 19 (CYFRA 21-1, CYFRA), and squamous cell carcinoma antigen (SCC)] and outcomes in patients with NSCLC treated with bevacizumab plus chemotherapy.
We retrospectively analysed 105 patients with NSCLC from the Czech TULUNG registry treated at University Hospital in Pilsen with bevacizumab plus chemotherapy. Response to therapy was tested by Fisher's exact test. Survival statistics were evaluated using the Kaplan-Meier method and Cox analysis.
Only normal values of CYFRA (not CEA or SCC) were associated with significantly better overall and progression-free survival in univariate analysis. We also observed a trend for a better disease control rate in patients with normal levels of CYFRA. In a multivariate Cox model, only CYFRA was associated with significantly better overall but not progression-free survival.
In our retrospective study, we point out the possibility of using CYFRA as a prognostic marker in patients with NSCLC treated with chemotherapy plus bevacizumab.
研究选定的肿瘤标志物[癌胚抗原（CEA）、细胞角蛋白 19 羧基末端（CYFRA 21-1、CYFRA）和鳞状细胞癌抗原（SCC）]与贝伐珠单抗联合化疗治疗非小细胞肺癌（NSCLC）患者结局之间的潜在关联。
我们回顾性分析了捷克 TULUNG 登记处的 105 例在比尔森大学医院接受贝伐珠单抗联合化疗的 NSCLC 患者。通过 Fisher 确切检验检测治疗反应。使用 Kaplan-Meier 方法和 Cox 分析评估生存统计数据。
仅 CYFRA（而非 CEA 或 SCC）的正常值与单因素分析中总生存期和无进展生存期的显著改善相关。我们还观察到 CYFRA 水平正常的患者疾病控制率有改善趋势。在多变量 Cox 模型中，仅 CYFRA 与总生存期显著相关，但与无进展生存期无关。
在我们的回顾性研究中，我们指出了在接受化疗联合贝伐珠单抗治疗的 NSCLC 患者中，使用 CYFRA 作为预后标志物的可能性。
